. Oms-|-maladie-À-virus-ebola,

. Disponible,

, Ebola : retour aux origines du virus-Sciencesetavenir.fr

, Maladie à virus Ebola-Ebola-Ministère des Affaires sociales et de la Santé

. Disponible,

. Lemonde, à la découverte du virus Ebola, 1976.

, Ebola Virus Disease Distribution Map | Ebola Hemorrhagic Fever | CDC, 2016.

. Ebola-gefahr-in and . Südafrika, Kapstadt entdecken!

, Filoviridae-Figures-Negative Sense RNA Viruses-Negative Sense RNA Viruses, 2011.

. Disponible,

A. Zhang, Z. A. Bornholdt, T. Liu, D. M. Abelson, D. E. Lee et al., The Ebola Virus Interferon Antagonist VP24 Directly Binds STAT1 and Has a Novel, Pyramidal Fold. Rey FA, éditeur, PLoS Pathog. 23 févr, vol.8, issue.2, p.1002550, 2012.

H. Feldmann, H. Klenk, and . Filoviruses, University of Texas Medical Branch at Galveston, Baron S, éditeur. Medical Microbiology, 1996.

, Communication Resources | Ebola Hemorrhagic Fever | CDC

. Disponible,

, Gouvernement du Canada Agence de la santé publique du Canada. Virus Ebola-Fiches techniques santé-sécurité: agents pathogènes, 2001.

. Disponible,

J. S. Towner, T. K. Sealy, M. L. Khristova, C. G. Albariño, S. Conlan et al., Newly Discovered Ebola Virus Associated with Hemorrhagic Fever Outbreak in Uganda. Basler CF, éditeur. PLoS Pathog, vol.4, p.1000212, 2008.

, Virology Images and Resources | IHII | UTMB

E. Leroy, S. Baize, and J. P. Gonzalez, Les fièvres hémorragiques à virus Ebola et Marburg: l'actualité des filovirus, Médecine Trop, vol.71, issue.2, pp.111-132, 2011.

D. Bwanika and . The, Great' Ebola Outbreak: A Pictorial, 2014.

. Drjohnmarksays, , 2014.

. Disponible,

S. Jun, M. R. Leuze, I. Nookaew, E. C. Uberbacher, M. Land et al., Ebolavirus comparative genomics. Greber U, éditeur, FEMS Microbiol Rev. sept, vol.39, issue.5, pp.764-78, 2015.

W. Tatiana, Analyse phylogénétique des souches du virus de la fièvre hémorragique Ebola et mise en évidence de souches atypiques

[. U. , Sciences & Techniques Biologiques, vol.273, 2007.

D. S. Goodsell, Ebola Virus Proteins. RCSB Protein Data Bank, 2014.

. Disponible,

J. E. Lee, M. L. Fusco, A. J. Hessell, W. B. Oswald, D. R. Burton et al., Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor, Nature. juillet, vol.454, issue.7201, pp.177-82, 2008.

, Structure of the Ebola Virus Glycoprotein Bound to an Antibody from a Human Survivor

. Disponible,

S. P. Soni and R. V. Stahelin, The Ebola Virus Matrix Protein VP40 Selectively Induces Vesiculation from Phosphatidylserine-enriched Membranes, J Biol Chem, vol.28, issue.48, pp.33590-33597, 2014.

Z. A. Bornholdt, T. Noda, D. M. Abelson, P. Halfmann, M. R. Wood et al., Structural Rearrangement of Ebola Virus VP40 Begets Multiple Functions in the Virus Life Cycle, Cell. août, vol.154, issue.4, pp.763-74, 2013.

T. Noda, H. Sagara, E. Suzuki, A. Takada, H. Kida et al., Ebola Virus VP40 Drives the Formation of Virus-Like Filamentous Particles Along with GP, J Virol. 15 mai, vol.76, issue.10, pp.4855-65, 2002.

L. D. Jasenosky, G. Neumann, I. Lukashevich, and Y. Kawaoka, Ebola Virus VP40-Induced Particle Formation and Association with the Lipid Bilayer, J Virol. 1 juin, vol.75, issue.11, pp.5205-5219, 2001.

R. N. Harty, M. E. Brown, G. Wang, J. Huibregtse, and F. P. Hayes, A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: Implications for filovirus budding, Proc Natl Acad Sci. 5 déc, vol.97, issue.25, pp.13871-13877, 2000.

E. Adu-gyamfi, S. Soni, C. Jee, M. Digman, E. Gratton et al., A Loop Region in the NTerminal Domain of Ebola Virus VP40 Is Important in Viral Assembly, Budding, and Egress. Viruses, vol.6, pp.3837-54, 2014.

Y. Huang, L. Xu, Y. Sun, and G. J. Nabel, The Assembly of Ebola Virus Nucleocapsid Requires Virion-Associated Proteins 35 and 24 and Posttranslational Modification of Nucleoprotein, Mol Cell. août, vol.10, issue.2, pp.307-323, 2002.

E. Mühlberger, M. Weik, V. E. Volchkov, H. Klenk, and S. Becker, Comparison of the Transcription and Replication Strategies of Marburg Virus and Ebola Virus by Using Artificial Replication Systems, J Virol. mars, vol.73, issue.3, pp.2333-2375, 1999.

T. Hoenen, A. Groseth, L. Kolesnikova, S. Theriault, H. Ebihara et al., Infection of Naïve Target Cells with Virus-Like Particles: Implications for the Function of Ebola Virus VP24, J Virol. juill, vol.80, issue.14, pp.7260-7264, 2006.

S. P. Reid, L. W. Leung, A. L. Hartman, O. Martinez, M. L. Shaw et al., Ebola Virus VP24 Binds Karyopherin ?1 and Blocks STAT1 Nuclear Accumulation, J Virol. juin, vol.80, issue.11, pp.5156-67, 2006.

M. D. Daugherty and H. S. Malik, How a Virus Blocks a Cellular Emergency Access Lane to the Nucleus, STAT! Cell Host Microbe. 13 août, vol.16, issue.2, pp.150-152, 2014.

B. Hartlieb, J. Modrof, E. Muhlberger, H. Klenk, and S. Becker, Oligomerization of Ebola Virus VP30 Is Essential for Viral Transcription and Can Be Inhibited by a Synthetic Peptide, J Biol Chem, vol.278, issue.43, pp.41830-41836, 2003.

W. B. Cardenas, Y. Loo, M. Gale, A. L. Hartman, C. R. Kimberlin et al., Ebola Virus VP35 Protein Binds Double-Stranded RNA and Inhibits Alpha/Beta Interferon Production Induced by RIG-I Signaling, J Virol. 1 juin, vol.80, issue.11, pp.5168-78, 2006.

. Futura, La stratégie à double tranchant du virus Ébola

. Futura,

. Disponible,

, ViralZone: Ebolavirus cycle

. Ebola,

. Ebola,

, Institut Pasteur

. Fièvre-hémorragique-virale, FHV) à virus Ebola / Maladies infectieuses / Dossiers thématiques / Accueil

, Survivants d'Ebola : questions-réponses | Fièvre hémorragique à virus Ebola | CDC

. Disponible,

, OMS | Organisation mondiale de la Santé

, WHO, p.12, 2016.

A. Marzi, T. Reinheckel, and H. Feldmann, Cathepsin B & L Are Not Required for Ebola Virus Replication, PLoS Negl Trop Dis, vol.6, issue.12

L. Virus and E. ,

. Les-crises and . Fr, , 2015.

. Disponible,

. Dr, . Gaüzière, . Pr, and . Aubry, Maladie à virus Ebola-Cours de médecine tropicale

. Disponible,

. Rfi, Ebola en 7 questions

R. ,

. Disponible,

. Ebola,

, Institut Pasteur, 2015.

, Guide opérationnel sur la lutte contre Ebola

. Croix-rouge-française,

, Conduite à tenir autour des cas suspects de fièvre hémorragique à virus Ebola, HCSP, 2014.

, Lignes directrices pour la collecte, le transport et la soumission d'échantillons destinés au test du virus Ebola | Fièvre hémorragique à virus Ebola | CDC

. Disponible,

. Ebola-symptômes, , 2016.

. Disponible,

. Diagnostic-rapide-d, Ebola : le test eZYSCREEN® fait ses preuves sur le terrain

S. Carraro-da, eZyscreen test a strisce per diagnosticare ebola in 15 minuti

. Scienzamente, , 2014.

. Disponible,

. Oms-|-maladie-À-virus-ebola, , 2016.

. Disponible,

, A la Une du Républicain Lorrain : toute l'actualité de la Moselle

L. 'épidémie-d, Ébola progresse en Afrique de l'Ouest

. Abidjan,

S. K. Gire, A. Goba, K. G. Andersen, R. Sealfon, D. J. Park et al., Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak, Science. 12 sept, vol.345, issue.6202, pp.1369-72, 2014.

I. , Ebola : quels sont les pays concernés par l'épidémie ?

. Franceinfo, , 2014.

. Disponible,

G. D. Maganga, J. Kapetshi, N. Berthet, K. Ilunga, B. Kabange et al., Ebola Virus Disease in the Democratic Republic of Congo, N Engl J Med, vol.371, issue.22, pp.2083-91, 2014.

, Ebola et autres fièvres hémorragiques-Activités | Médecins Sans Frontières, p.12, 2016.

. Oms-|-reportages, maladie à virus Ebola

. Oms-|-l, équipement de protection individuelle dans le cadre de la riposte à la flambée d'infections à filovirus

C. , Caisse des Français de l'Etranger, 2016.

. Disponible,

, Mission des Nations Unies pour l'action d'urgence contre l'Ebola (MINUAUCE) [Internet]. Action mondiale de lutte contre l'Ebola, 2015.

. Disponible,

, Ebola-Maladies infectieuses-Ministère des Affaires sociales et de la Santé

. Disponible,

V. ,

F. Diplomatie, Ministère des Affaires étrangères et du Développement international, 2016.

, Ebola : le nouveau centre de traitement MSF au Liberia déjà débordé par le nombre de patients-Articles | Médecins Sans Frontières

. Disponible,

F. Ebola, , 2016.

. Disponible,

, Ebola : « Le chlore est notre meilleur allié

S. International, , 2017.

, Le centre de traitement Ebola de Macenta accueille ses premiers patients

C. Française, , 2016.

, Urgence Ebola-Dossiers | Médecins Sans Frontières, 2016.

. Disponible,

. Infographie, Visite d'un centre de traitement d'Ebola-Sciencesetavenir.fr

, Témoignage d'un patient guéri d'Ebola : « Ebola, ce n'est pas forcément la mort

. Disponible,

. Dyary-hiewa-othman, H. S. Rahman, H. H. Othman, R. Abdullah, and M. S. Chartrand, Advancements in the Therapy of Ebola Virus Disease. Pediatr Infect Dis Open Access, 2016.

. Disponible,

E. Gignoux, A. S. Azman, M. De-smet, P. Azuma, M. Massaquoi et al., Effect of Artesunate-Amodiaquine on Mortality Related to Ebola Virus Disease, N Engl J Med. 7 janv, vol.374, issue.1, pp.23-32, 2016.

. Oms-|-traitements and . Interventions-contre-le-virus-ebola, , 2016.

, OMS | Traitements et vaccins potentiels contre le virus Ebola, 2016.

. Disponible,

L. V. Eeckhout, Trois traitements expérimentaux contre Ebola autorisés en France. Le Monde.fr [Internet]. 19 sept, 2014.

. Disponible,

J. R. Kugelman, M. Sanchez-lockhart, K. G. Andersen, S. Gire, D. J. Park et al., Evaluation of the Potential Impact of Ebola Virus Genomic Drift on the Efficacy of Sequence-Based Candidate Therapeutics. mBio, 27 févr, vol.6, issue.1, pp.2227-2241, 2015.

, Le virus Ebola s'est adapté à mieux infecter l'homme lors de l'épidémie de, pp.2013-2016

, Institut Pasteur

. Disponible,

J. Griensven, T. Edwards, X. De-lamballerie, M. G. Semple, P. Gallian et al., Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea, N Engl J Med. 7 janv, vol.374, issue.1, pp.33-42, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01252702

N. M. Kudoyarova-zubavichene, N. N. Sergeyev, A. A. Chepurnov, and S. V. Netesov, Preparation and Use of Hyperimmune Serum for Prophylaxis and Therapy of Ebola Virus Infections, J Infect Dis. févr, vol.179, issue.s1, pp.218-241, 1999.

, Memoire Online-Utilisation des produits biologiques d'origine équine en thérapeutique humaine-Geraud Chancelin HELLOW TEJIOZEM

M. Online, , p.21

X. Zheng, G. Wong, Y. Zhao, H. Wang, S. He et al., Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection, Sci Rep. 12 avr, vol.6, p.24179, 2016.

, Antibody Fragmentation | Innova Biosciences

T. M. Zmapp,

M. Biopharmaceutical and . Inc, , 2016.

. Disponible,

. Disponible,

E. Tran, E. A. Nelson, P. Bonagiri, J. A. Simmons, C. J. Shoemaker et al., Mapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular Entry. Sundquist WI, éditeur, J Virol. 1 sept, vol.90, issue.17, pp.7618-7645, 2016.

, OGM contre Ebola-Afis-Association française pour l'information scientifique, 2016.

X. Qiu, G. Wong, J. Audet, A. Bello, L. Fernando et al., Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp, Nature, vol.29, issue.2014

. Disponible,

P. The and . Group, A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection, N Engl J Med, vol.375, issue.15, pp.1448-56, 2016.

, WHO | Table of drug clinical trials, 2016.

. Disponible,

, Bavituximab Oncology

, Peregrine Pharmaceuticals PPHM Board [Internet]. Investors Hub

. Disponible,

S. D. Dowall, V. A. Graham, K. Corbin-lickfett, C. Empig, K. Schlunegger et al., Effective Binding of a Phosphatidylserine-Targeting Antibody to Ebola Virus Infected Cells and Purified Virions, J Immunol Res, vol.2015, pp.1-9, 2015.

, BioCryst Pharmaceuticals Inc, p.4430

. Disponible,

R. Taylor, P. Kotian, T. Warren, R. Panchal, S. Bavari et al., BCX4430-A broadspectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease, J Infect Public Health. mai, vol.9, issue.3, pp.220-226, 2016.

B. Pharmaceuticals, BioCryst Announces Positive Study Results for BCX4430 Delayed Treatment of Ebola Virus Infection in a Non-Human Primate Model

G. News-room, Positive-Study-Results-for-BCX4430-Delayed-Treatment-of-Ebola-Virus-Infection-in-aNon-Human-Primate-Model.html, 2016.

, A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430Full Text View-ClinicalTrials.gov [Internet

I. Field and |. Toyama-chemical, , 2016.

. Disponible,

, The New Drug Application Approval of "AVIGAN? Tablet 200mg" in Japan for the anti-influenza virus drug

L. Oestereich, A. Lüdtke, S. Wurr, T. Rieger, C. Muñoz-fontela et al., Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model, Antiviral Res. mai, vol.105, pp.17-21, 2014.

D. Sissoko, C. Laouenan, E. Folkesson, M. 'lebing, A. Beavogui et al., Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. Lipsitch M, éditeur, PLOS Med. 1 mars, vol.13, issue.3, p.1001967, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01327168

, Résultats préliminaires de l'essai clinique JIKI visant à tester l'efficacité du favipiravir pour réduire la mortalité chez les personnes infectées par le virus Ebola en Guinée

, Résultats définitifs de l'essai JIKI

. Salle-de-presse-|-inserm, Treatment of Ebola virus infection with brincidofovir, 2016.

. Disponible,

, Chimerix's Brincidofovir Selected for Use in Ebola Clinical Trial in West Africa by International Consortium (NASDAQ:CMRX)

L. M. Smith, L. E. Hensley, T. W. Geisbert, J. Johnson, A. Stossel et al., InterferonTherapy Prolongs Survival in Rhesus Macaque Models of Ebola and Marburg Hemorrhagic Fever, J Infect Dis. 15 juill, vol.208, issue.2, pp.310-318, 2013.

B. A. Rhein, L. S. Powers, K. Rogers, M. Anantpadma, B. K. Singh et al., Interferon-? Inhibits Ebola Virus Infection. Schnell MJ, éditeur, PLOS Pathog, vol.11, issue.11, p.1005263, 2015.

J. Cohen, Special report: Ebola's thin harvest, vol.31

. Disponible,

, TDR | New trial of TKM-Ebola treatment to start in Sierra Leone, 2016.

, Tekmira Provides Update on TKM-Ebola-Guinea, 2016.

, Ebola Virus Infection: a review on the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials-document

K. A. Whitehead, R. Langer, and D. G. Anderson, Knocking down barriers: advances in siRNA delivery, Nat Rev Drug Discov. févr, vol.8, issue.2, pp.129-167, 2009.

T. W. Geisbert, A. C. Lee, M. Robbins, J. B. Geisbert, A. N. Honko et al., Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study, The Lancet. mai, vol.375, issue.9729, pp.1896-905, 2010.

, Experimental Ebola drug shelved; study explores virus clearance

, CIDRAP, 2016.

. Disponible,

C. Koons, C. Chen, and R. Langreth, Ebola Drug by Tekmira May Be Used on Infected Patients, vol.8

. Disponible,

E. P. Thi, C. E. Mire, A. Lee, J. B. Geisbert, J. Z. Zhou et al., Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates, Nature. 22 avr, vol.521, issue.7552, pp.362-367, 2015.

E. J. Mendoza, X. Qiu, and G. P. Kobinger, Progression of Ebola Therapeutics During the 20142015 Outbreak, Trends Mol Med. 1 févr, vol.22, issue.2, pp.164-73, 2016.

J. Dunning, F. Sahr, A. Rojek, F. Gannon, G. Carson et al., Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial. von Seidlein L, éditeur, PLOS Med. 19 avr, vol.13, issue.4, p.1001997, 2016.

, AVI-7537) Drug Therapy (Sarepta Therapeutics) for Treating Ebola Virus Disease, ECRI Institute, vol.6002

P. Iversen, T. Warren, J. Wells, N. Garza, D. Mourich et al., Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses, vol.4, pp.2806-2836, 2012.

T. K. Warren, C. A. Whitehouse, J. Wells, L. Welch, A. E. Heald et al., A Single Phosphorodiamidate Morpholino Oligomer Targeting VP24 Protects Rhesus Monkeys against Lethal Ebola Virus Infection. mBio, 27 févr, vol.6, issue.1, pp.2344-2358, 2015.

A. E. Heald, P. L. Iversen, J. B. Saoud, P. Sazani, J. S. Charleston et al., Safety and Pharmacokinetic Profiles of Phosphorodiamidate Morpholino Oligomers with Activity against Ebola Virus and Marburg Virus: Results of Two Single-Ascending-Dose Studies

, Antimicrob Agents Chemother, vol.58, issue.11, pp.6639-6686, 2014.

, ARCA biopharma Receives FDA Orphan Drug Designation for rNAPc2 as a Potential Treatment for Ebola | Business Wire, p.15, 2014.

T. W. Geisbert, L. E. Hensley, P. B. Jahrling, T. Larsen, J. B. Geisbert et al., Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys, The Lancet. déc, vol.362, issue.9400, pp.1953-1961, 2003.

, Ebola news n°10, mars 2016 | Société Française de Médecine de Catastrophe, 2016.

O. Reynard, X. Nguyen, A. , N. Barateau, V. Cimarelli et al., Identification of a New Ribonucleoside Inhibitor of Ebola Virus Replication, Viruses. 1 déc, vol.7, issue.12, pp.6233-6273, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01911432

, OMS | Innocuité de 2 vaccins candidats contre le virus Ebola

. Disponible,

, OMS sur l'accès aux vaccins contre la maladie à virus Ebola et le financement de ces vaccins

|. Ebola-&-marburg and . Nih, , 2016.

S. Sridhar, Clinical development of Ebola vaccines, Ther Adv Vaccines. sept, vol.3, p.125, 2015.

J. E. Ledgerwood, A. D. Dezure, D. A. Stanley, L. Novik, M. E. Enama et al., Chimpanzee Adenovirus Vector Ebola Vaccine-Preliminary Report, N Engl J Med, p.150126054808000, 2014.

, OMS | Innocuité de 2 vaccins candidats contre le virus Ebola

, Deux vaccins contre Ebola passent en phase 3

L. Quotidien-du-médecin, , 2016.

, Initial results of Ebola vaccine trials in Kenya show it is safe-News [Internet]. [cité 30 mai, 2017.

S. M. Jones, H. Feldmann, U. Ströher, J. B. Geisbert, L. Fernando et al., Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses, Nat Med. juill, vol.11, issue.7, pp.786-90, 2005.

C. Pallier, Un vaccin contre les virus Ebola et Marburg : des résultats prometteurs. Virologie. 30 sept, vol.9, pp.413-417, 2005.

A. Marzi, S. J. Robertson, E. Haddock, F. Feldmann, P. W. Hanley et al., VSVEBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain, Science. 14 août, vol.349, issue.6249, pp.739-781, 2015.

A. Marzi, P. W. Hanley, E. Haddock, C. Martellaro, G. Kobinger et al., Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona, J Infect Dis, vol.214, issue.3, pp.360-366, 2016.

, OMS | Innocuité de 2 vaccins candidats contre le virus Ebola

A. M. Henao-restrepo, I. M. Longini, M. Egger, N. E. Dean, W. J. Edmunds et al., Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial, The Lancet. août, vol.386, issue.9996, pp.857-66, 2015.

S. Leone, Trial to Introduce a Vaccine against Ebola (STRIVE) Q&A | Ebola Hemorrhagic Fever | CDC

T. M. Vesiculovax and . Prophylactic, , 2016.

. Disponible,

, Profectus Ebola Vaccine Ph1 Initiation, 2016.

. Disponible,

I. D. Milligan, M. M. Gibani, R. Sewell, E. A. Clutterbuck, D. Campbell et al., Safety and Immunogenicity of Novel Adenovirus Type 26-and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial, JAMA. 19 avr, vol.315, issue.15, p.1610, 2016.

. Johnson-&-johnson, Lancement d'une étude sur le virus Ebola, 2016.

, Inserm recrute environ 300 volontaires pour un essai vaccinal contre le virus Ebola, 2015.

, Interruption d'un essai clinique pour un vaccin contre Ebola, 2016.

, A Study to Assess Safety Tolerability and Immunogenicity of Three Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults-Full Text View-ClinicalTrials

, A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants-Full Text View-ClinicalTrials

. Disponible,

, Inovio Ebola Vaccine Generates Robust Immune Responses in Humans, 2016.

, Inovio Pharmaceuticals Expands Positive Phase I Ebola Vaccine Trial to Identify Most Optimal Immunization Regimen, 2016.

, Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers-Full Text View-ClinicalTrials

. Disponible,

, Présidente internationale de MSF, devant les Nations Unies-Publications | Médecins Sans Frontières

. Disponible,

, OMS | Rapport du Groupe d'experts chargé de l'évaluation intérimaire de la riposte à Ebola

W. , , 2016.

. Disponible,

, OMS | Règlement sanitaire international, 2005.

. Disponible,